Cartesian Therapeutics, Inc. — Director's Dealing 2020

Mar 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2020-03-01

Reporting Person: Brunn Carsten (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-01	Common Stock	M	10937	—	Acquired	81851	Direct
2020-03-03	Common Stock	S	3374	$3.8564	Disposed	78477	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-01	Restricted Stock Units	$	M	10937	Disposed		Common Stock (10937.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.85 to $3.87. The Reporting Person undertakes to provide upon request to theSEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: This restricted stock unit vests as to 25% on December 1, 2019. The remainder of the units will vest in twelve substantially equal quarterly installments thereafter. The restricted stock units have no expiration date.